403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Oncolytics Biotech Inc
(MENAFN- Baystreet) 10:40 AM EST - Oncolytics Biotech Inc: Announced initial data from a preclinical study evaluating pelareorep in combination with RAS inhibitor modalities in a solid tumor model, which demonstrate evidence of greater anti-tumor activity in combination than with the individual approaches alone. Based on these findings, the Company is planning additional studies in models of pancreatic ductal adenocarcinoma and colorectal cancer designed to further evaluate the combinations' effects on immune activation, tumor response durability, and time-to-resistance. Oncolytics Biotech Inc
shares N are trading up $0.10 at $1.14.
Full Press Release:
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment